13F-HR filed by Catalio Capital Management, LP
Catalio Capital Management, LP filed this 13F-HR for the quarter ended 2026-09-30, accepted by EDGAR 2026-11-16 20:32:55 UTC, with 47 holding rows worth $538,308,196.
- Accession
- 0001958125-26-000012
- Filer
- CIK 1958125
- Filed
- 2026-11-16
- Accepted by EDGAR
- Ingested
- Source
- EDGAR live feed
13F report for Q3 2026
A holdings report, 47 entries on the cover page, a total value of $538,308,196 stated on the cover page (in dollars after the unit check, H1), rows summing to $538,308,196 with VALUE read as dollars as filed, 13F file number 028-25237. The quarter's positions are built on this report. The resolved quarter.
The information table after summing rows of one CUSIP and put or call (H4), with the CUSIP and issuer name as filed. Values in dollars after the unit check (method).
| Issuer as filed | CUSIP | Class | Amount | Value | Value read as | Type |
|---|---|---|---|---|---|---|
| AVALYN PHARMA INC | 05348Y105 | COMMON STOCK | 1,698,851 | $48,400,265 | dollars as filed | |
| Bristol-Myers Squibb Company | 110122108 | COM | 499,716 | $31,182,278 | dollars as filed | |
| BRIDGEBIO PHARMA INC | 10806X102 | COM | 425,111 | $27,972,304 | dollars as filed | |
| PARABILIS MEDICINES INC COM | 698955101 | Stock | 824,043 | $26,608,348 | dollars as filed | |
| Johnson & Johnson | 478160104 | COM | 99,496 | $26,340,571 | dollars as filed | |
| ASCENDIS PHARMA A/S | K08588103 | ORD SHS *A* | 101,445 | $23,112,214 | dollars as filed | |
| ARROWHEAD PHARMACEUTICALS IN | 04280A100 | COM | 315,247 | $20,632,916 | dollars as filed | |
| SYNDAX PHARMACEUTICALS INC | 87164F105 | COM | 1,023,510 | $19,241,988 | dollars as filed | |
| DEFINIUM THERAPEUTICS INC | 24477V105 | COM SHS | 497,964 | $18,952,510 | dollars as filed | |
| CELCUITY INC | 15102K100 | COM | 230,609 | $18,338,028 | dollars as filed | |
| SEPTERNA INC COM | 81734D104 | Stock | 454,015 | $17,765,607 | dollars as filed | |
| GUARDANT HEALTH INC COM | 40131M109 | Stock | 92,579 | $16,512,390 | dollars as filed | |
| PROTAGONIST THERAPEUTICS | 74366E102 | COM | 112,418 | $15,838,572 | dollars as filed | |
| 10X GENOMICS INC CL A COM | 88025U109 | Stock | 164,029 | $14,821,660 | dollars as filed | |
| AMYLYX PHARMACEUTICALS INC | 03237H101 | COM | 505,882 | $14,721,166 | dollars as filed | |
| MINERALYS THERAPEUTICS INC | 603170101 | COM | 583,364 | $14,659,937 | dollars as filed | |
| EDWARDS LIFESCIENCES CORP COM | 28176E108 | Stock | 161,121 | $13,907,965 | dollars as filed | |
| CORVUS PHARMACEUTICALS INC | 221015100 | COM | 1,021,499 | $11,767,668 | dollars as filed | |
| VERADERMICS INC | 922967104 | COMMON STOCK | 95,646 | $11,595,165 | dollars as filed | |
| ENTERA BIO LTD | M40527109 | SHS | 3,921,568 | $11,411,763 | dollars as filed | |
| DISC MEDICINE INC COM | 254604101 | Stock | 172,709 | $11,305,531 | dollars as filed | |
| Odyssey Therapeutics, Inc. | 67613T104 | COMMON STOCK | 457,839 | $10,173,183 | dollars as filed | |
| 4D MOLECULAR THERAPEUTICS INC COM | 35104E100 | Stock | 684,753 | $9,798,815 | dollars as filed | |
| ULTRAGENYX PHARMACEUTICAL IN | 90400D108 | COM | 601,760 | $9,044,453 | dollars as filed | |
| BIOMARIN PHARMACEUTICAL INC | 09061G101 | COM | 144,971 | $8,698,260 | dollars as filed | |
| ANNEXON INC | 03589W102 | COM | 1,986,806 | $8,404,189 | dollars as filed | |
| RHYTHM PHARMACEUTICALS INC | 76243J105 | COM | 85,614 | $8,151,737 | dollars as filed | |
| STRUCTURE THERAPEUTICS INC COMP | 86366E106 | EQUITY | 260,109 | $8,133,608 | dollars as filed | |
| NEKTAR THERAPEUTICS | 640268306 | COMMON STOCK | 126,817 | $7,678,135 | dollars as filed | |
| IMMUNOCORE HLDGS PLC ADS | 45258D105 | ADR | 211,985 | $6,421,026 | dollars as filed | |
| COGENT BIOSCIENCES INC | 19240Q201 | COM | 167,716 | $5,370,266 | dollars as filed | |
| KAILERA THERAPEUTICS INC | 482931102 | COMMON STOCK | 468,750 | $5,353,125 | dollars as filed | |
| NATERA INC COM | 632307104 | Stock | 12,530 | $5,178,774 | dollars as filed | |
| FRACTYL HEALTH INC | 35168W103 | COM | 8,841,707 | $4,813,425 | dollars as filed | |
| KARDIGAN INC | 485925101 | CMN | 312,500 | $4,609,375 | dollars as filed | |
| ELEDON PHARMACEUTICALS INC | 28617k101 | COM | 1,637,114 | $4,141,898 | dollars as filed | |
| HEARTFLOW INC | 42238D107 | COM | 74,969 | $3,729,708 | dollars as filed | |
| BRIDGEBIO ONCOLOGY THERAPEUT | 107924102 | COM NEW | 699,532 | $2,868,081 | dollars as filed | |
| KORSANA BIOSCIENCES INC | 23255M303 | COMMON STOCK | 87,702 | $2,806,464 | dollars as filed | |
| FREENOME INC | 35661P100 | COMMON STOCK | 158,170 | $2,491,178 | dollars as filed | |
| PROTARA THERAPEUTICS INC | 74365U107 | COM STK | 512,287 | $1,562,475 | dollars as filed | |
| KARYOPHARM THERAPEUTICS INC | 48576U205 | COMMON STOCK | 976,191 | $1,190,953 | dollars as filed | |
| HYPERFINE INC | 44916K106 | Common Stock | 1,303,155 | $1,052,949 | dollars as filed | |
| METAGENOMI THERAPEUTICS INC | 59102M104 | COM | 528,993 | $560,733 | dollars as filed | |
| FAETH THERAPEUTICS INC | 81728A207 | COM NEW | 14,718 | $437,713 | dollars as filed | |
| OUTSET MED INC | 690145206 | COM NEW | 107,456 | $322,368 | dollars as filed | |
| ADARx Pharmaceuticals, Inc. | 00654F105 | Common Stock, par value $0.0001 per share | 11,357 | $226,459 | dollars as filed |
Amendment chain
| Filing | Role | Filed | Accepted | Ingested |
|---|---|---|---|---|
| 13F-HR 0001958125-26-000012 | this filing | 2026-11-16 |